Trial Profile

A Phase 2, Parallel, Randomized, Open-label, Controlled Study of EG-301 150 Mg Daily in Patients with Nonfocal Geographic Atrophy Secondary to DAMD

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EG 301 (Primary) ; Ascorbic acid/betacarotene/copper(II) oxide/tocopherol/zinc oxide
Indications Dry macular degeneration
Focus Adverse reactions; Therapeutic Use
Sponsors Evergreen Therapeutics

Most Recent Events

09 Sep 2024 Planned End Date changed from 1 Sep 2025 to 1 Jun 2026.
09 Sep 2024 Planned primary completion date changed from 1 Sep 2025 to 1 Jun 2026.
09 Sep 2024 Planned initiation date changed from 1 Sep 2024 to 1 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com